Akums Drugs and Pharmaceuticals Limited Sustainability Profile
Akums Drugs and Pharmaceuticals Limited, a prominent player in the Indian pharmaceutical industry, is headquartered in Haridwar, Uttarakhand. Founded in 2004, the company has rapidly established itself as a leading manufacturer of a diverse range of pharmaceutical products, including formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. With a strong focus on quality and innovation, Akums serves both domestic and international markets, catering to various therapeutic segments. The company is renowned for its state-of-the-art manufacturing facilities, which adhere to stringent regulatory standards, ensuring the delivery of high-quality medicines. Akums has achieved significant milestones, including numerous certifications and partnerships, solidifying its position as a trusted name in healthcare. Its commitment to excellence and customer satisfaction continues to drive its growth and reputation in the competitive pharmaceutical landscape.
DitchCarbon Score
How does Akums Drugs and Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akums Drugs and Pharmaceuticals Limited's score of 11 is lower than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akums Drugs and Pharmaceuticals Limited's reported carbon emissions
In 2023, Akums Drugs and Pharmaceuticals Limited reported total carbon emissions of 20,000,000 kg CO2e, comprising 10,000,000 kg CO2e from Scope 1 and 10,000,000 kg CO2e from Scope 2. The company has not disclosed any Scope 3 emissions data. For 2024, emissions data is not yet available, but the company reported a CO2 emissions intensity of approximately 4,470 kg CO2e per tonne of Active Pharmaceutical Ingredient (API) produced. Despite the significant emissions reported, Akums has not established specific reduction targets or initiatives, nor have they committed to any climate pledges or SBTi targets. The emissions intensity metrics indicate a focus on improving efficiency in relation to revenue and production, with emissions intensity per INR million of revenue reported at about 0.0000001 kg CO2e. Overall, while Akums Drugs and Pharmaceuticals Limited has made strides in measuring their emissions, the absence of reduction commitments highlights an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 10,000,000 |
| Scope 2 | 10,000,000 |
| Scope 3 | - |
How Carbon Intensive is Akums Drugs and Pharmaceuticals Limited's Industry?
How Carbon Intensive is Akums Drugs and Pharmaceuticals Limited's Location?
Akums Drugs and Pharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Akums Drugs and Pharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
